 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- Zeyzelf (rivastigmine twice weekly) / Luye Group, Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / Novartis, EVER Pharma
Efficacy of Pharmacotherapies in Improving Cognitive Function in Vascular Dementia: A Network Meta-analysis of Randomized Controlled Trials (Colorado Convention Center | Exhibit Hall B-E) - Mar 8, 2024 - Abstract #AAN2024AAN_4428;
Rivastigmine also shows improvement. Additionally, Donepezil and Memantine demonstrate cognitive benefits, as measured by MMSE.
- || Zeyzelf (rivastigmine twice weekly) / Luye Group
New P1 trial: Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (13.3mg/24h) (clinicaltrials.gov) - May 10, 2023
P1, N=48, Recruiting, Sponsor: Luye Pharma Group Ltd.
- || Rivalif (rivastigmine multi day transdermal patch) / Luye Group
Clinical: Comparative Bioavailability study of a Novel Multi-day Patch Formulation of Rivastigmine (twice weekly) with Exelon® Transdermal Patch (daily). A randomized clinical trial. (Pubmed Central) - Nov 16, 2022
P1
Patch adhesion favored RID-TDS despite the longer dosing interval. Both products were well tolerated.
- | rivastigmine transdermal / Generic mfg.
Trial completion: Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (9.5mg/24h) (clinicaltrials.gov) - Sep 18, 2019
P1, N=58, Completed, Sponsor: SocraTec R&D GmbH
Both products were well tolerated. Recruiting --> Completed
- | donepezil / generics, galantamine hydrobromide / generics, rivastigmine / generics
Retrospective data, Review, Journal, HEOR: Comparative Effectiveness and Safety of Cognitive Enhancers for Treating Alzheimer's Disease: Systematic Review and Network Metaanalysis. (Pubmed Central) - Sep 7, 2019
An exhaustive review of the literature involving 142 studies demonstrated that cognitive enhancers in general have minimal effects on cognition according to minimal clinically important difference and global ratings. The drugs appear safe, but this must be interpreted cautiously because trial participants may have less comorbidity and fewer adverse effects than those treated with these drugs in clinical practice.
- | rivastigmine transdermal / Generic mfg.
New P1 trial: Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (9.5mg/24h) (clinicaltrials.gov) - Sep 5, 2018
P1, N=58, Recruiting, Sponsor: SocraTec R&D GmbH